Clinical Trial Update: Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases [Phase 4]

View source ↗

Summary

Phase 4 trial update on zoledronic acid to prevent skeletal-related events in hormone-refractory and hormone-sensitive prostate cancer with bone metastases; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: Novartis | Conditions: Prostate Cancer | Phase 4 | Status: COMPLETED